No Data
No Data
Barclays Maintains Nurix Therapeutics(NRIX.US) With Buy Rating, Maintains Target Price $31
Truist Financial Maintains Nurix Therapeutics(NRIX.US) With Buy Rating
Truist Financial Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)
Nurix Therapeutics Sees Cash Runway Into 1H27
Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases
Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
EmotionOutOfEquation : Already 500% current year where is yearly bottom of strong buy potential
EmotionOutOfEquation : Time to make separate watchlist of strong buys so get better cost price for less red days